Stay updated on AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial

Sign up to get notified when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the FVIII activity profile after dosing with SB-525 (PF-07055480) in subjects with severe Hemophilia A.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:39.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for study participants, including specific health conditions and prior treatments required for inclusion, as well as exclusion criteria.
    Difference
    17%
    Check dated 2024-05-22T20:26:57.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:14:20.000Z thumbnail image

Stay in the know with updates to AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.